AEGIS LLC

Registrant on federal lobbying filings · filed 2025 to 2026

$660,000 Income reported

2 Clients represented

12 Filings counted

0 Former members lobbying

Income is the fees this registrant reported being paid to lobby. Everything on this page is grouped by the registrant's LDA id (401108688), not by name.

Clients 2

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA $360,000 6 filings
TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS FKA TRIS $300,000 6 filings

Lobbyists named 1

ANNE ELIZABETH ESPOSITO 12 filings · through 2026 Health Policy Coordinator, Energy and Commerce Committee; Health Policy Advisor, Health Subcommittee (Chairman Bilirakis)

A lobbyist who previously held a covered government position must disclose it. We flag the ones whose name resolves to a member of Congress and link the ones still in our roster. The revolving door collects them across every firm.

Reported by year 2 years

2026 $220,000 4 filings
2025 $440,000 8 filings

Issues lobbied 2

Pharmacy 12
Health Issues 6

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 3

HOUSE OF REPRESENTATIVES 12
SENATE 12
Natl Highway Traffic Safety Administration (NHTSA) 3

Recent filings 12 total

Q2

TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS FKA TRIS

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $50,000 income · posted Jul 2, 2026

View → Q2

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $60,000 income · posted Jul 2, 2026

View → Q1

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $60,000 income · posted Apr 7, 2026

View → Q1

TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS FKA TRIS

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $50,000 income · posted Apr 7, 2026

View → Q4

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $60,000 income · posted Jan 12, 2026

View → Q4

TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS FKA TRIS

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $50,000 income · posted Jan 12, 2026

View → Q3

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

3rd Quarter (July 1 - Sep 30) 2025 · House · Senate · $60,000 income · posted Oct 10, 2025

View → Q3

TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS FKA TRIS

3rd Quarter (July 1 - Sep 30) 2025 · House · Senate · $50,000 income · posted Oct 10, 2025

View → Q2

TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS FKA TRIS

2nd Quarter (Apr 1 - June 30) 2025 · House · Senate · $50,000 income · posted Jul 18, 2025

View → Q2

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

2nd Quarter (Apr 1 - June 30) 2025 · House · Senate · $60,000 income · posted Jul 18, 2025

View → Q1

TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS FKA TRIS

1st Quarter (Jan 1 - Mar 31) 2025 · House · Senate · $50,000 income · posted Apr 4, 2025

View → Q1

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

1st Quarter (Jan 1 - Mar 31) 2025 · House · Senate · $60,000 income · posted Apr 4, 2025

View →

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.